For centuries, natural kratom leaves from the Mitragyna speciosa tree have been chewed or brewed as tea by communities in Thailand, Malaysia, and other parts of Southeast Asia, where they have been used to combat fatigue, enhance work endurance, and manage minor aches in everyday life. In this traditional context, people consumed whole leaves or simple preparations, not purified or chemically altered extracts, and exposure to the plant’s most potent opioid-like component, 7-hydroxymitragynine (7-OH), remained minimal.
That distinction between natural kratom and concentrated 7-OH is at the heart of a growing public health debate, as regulators attempt to address the risks posed by novel, highly potent 7-OH products without erasing the historical and cultural reality of kratom’s more modest traditional use. Natural kratom leaf contains dozens of alkaloids, including mitragynine as the dominant compound and only trace levels of 7-OH, whereas modern 7-OH products isolate or synthetically amplify a single molecule into something closer to a pharmaceutical-strength opioid.
7-OH products have attracted sharp warnings from regulators, who describe them as potent opioid products with no approved medical uses and an emerging record of serious adverse events. In a recent advisory titled “Products Containing 7-OH Can Cause Serious Harm”, the FDA stresses that concentrated 7-OH ingredients used in dietary supplements, foods, or self-styled “therapeutic” products have not met basic safety standards and should be avoided, especially when marketed as treatments for pain, anxiety, mood disorders, or opioid withdrawal.
Natural kratom’s perceived benefits are largely observational, but they paint a consistent picture of why people continue to seek out whole-leaf products despite regulatory uncertainty. Surveys and small observational studies have found that many users report using natural kratom for reasons such as managing chronic pain, improving mood, enhancing focus, or self-managing symptoms related to anxiety and substance use, often as an alternative to more traditional pharmaceuticals; the National Institute on Drug Abuse notes that users describe both stimulant-like and opioid-like effects depending on dose, with lower doses often associated with increased alertness and higher doses linked to sedation and pain relief. These self-reports do not constitute proof of medical efficacy, yet they highlight real-world motivations that help explain kratom’s growing presence in Western markets.
The scientific literature around kratom is still developing, but some laboratory and preclinical studies have examined how mitragynine and related alkaloids interact with opioid receptors and other systems in the body, including adrenergic and serotonergic pathways, to produce complex effects that cannot be reduced to a single mechanism. A technical brief from the Michigan Department of Health reviewing kratom and its alkaloids describes mitragynine as a partial agonist at the mu-opioid receptor and notes that the plant’s diverse alkaloid profile may contribute to both its perceived benefits and its risks, particularly when products are contaminated, adulterated, or consumed in high doses; importantly, the brief also emphasizes that human data are limited and that more research is needed before kratom can be characterized as safe or effective for any medical indication.
In traditional use settings, kratom has often been consumed in relatively low doses throughout the day by agricultural workers seeking sustained energy and relief from fatigue, a pattern that differs markedly from the concentrated capsules, extracts, and shots sold in many Western markets today. Historical accounts from Southeast Asia suggest that, in those contexts, kratom’s risks were framed more around dependence and withdrawal with long-term heavy use, rather than acute overdoses or life-threatening toxicity, although modern toxicology work has shown that combining kratom with other substances, or using highly concentrated products, can significantly increase danger.
When we shift attention from natural kratom to 7-OH, the risk profile changes dramatically. 7-hydroxymitragynine is a metabolite and minor constituent of the kratom plant, but when isolated, chemically enhanced, or synthesized, it becomes a highly potent mu-opioid receptor agonist, with studies indicating that its analgesic potency can far exceed that of morphine; a scientific assessment prepared for the U.S. Food and Drug Administration on 7-OH describes it as a “novel opioid” with a significant potential for abuse and serious health harms, and it forms the basis of the agency’s recommendation that certain 7-OH products be considered for scheduling under the Controlled Substances Act.
Health authorities have already documented a troubling pattern of adverse events linked to 7-OH exposures. America’s Poison Centers report that from January through July 2025, poison centers recorded a sharp increase in kratom-related exposure cases and a growing subset involving 7-OH specifically, with more than one-third of patients exposed to 7-OH alone experiencing serious medical outcomes and most requiring treatment at healthcare facilities; symptoms associated with 7-OH use include nausea, vomiting, agitation, confusion, rapid heart rate, high blood pressure, breathing difficulties, excessive sleepiness, loss of consciousness, and seizures, prompting the organization to issue a public health advisory urging consumers to avoid products with 7-OH as an ingredient.
Moreover, the FDA has received reports of addiction, anxiety, depression, gastrointestinal distress, insomnia, seizures, and withdrawal symptoms following 7-OH exposure, and warns that the intense opioid-like nature of these products may encourage repeated use and rapid development of tolerance. Because 7-OH products are often marketed online and in retail outlets as dietary supplements, energy boosters, or mood enhancers, but are neither standardized nor subject to rigorous pre-market testing, consumers may have little idea of the true potency of what they are taking, or the extent to which these products differ from traditional kratom leaf.
The challenge for journalists, policymakers, and consumers is to distinguish between the relatively low-level exposure to 7-OH that occurs when people use natural kratom leaf and the high-intensity exposure associated with isolated or synthetic 7-OH ingredients. A recent evidence review published by researchers and archived on the U.S. National Library of Medicine’s PubMed Central platform traces this evolution from traditional kratom use to modern 7-OH products and notes that under traditional consumption patterns, the body’s exposure to 7-OH is minimal because it exists only in trace amounts, while contemporary products can deliver doses several times higher than those encountered in nature, radically altering the risk landscape.
Proponents of natural kratom argue that the plant’s full-spectrum alkaloid profile, combined with its long history of use in Southeast Asia, suggests a fundamentally different risk-benefit balance compared to isolated 7-OH. They point out that, while kratom use is not without harms—particularly when products are contaminated, used heavily over time, or combined with other drugs—its effects are mediated by a complex interaction of dozens of alkaloids, some of which may limit the respiratory depressant effects typically associated with traditional opioids; meanwhile, removing 7-OH from that context, concentrating it, and selling it as a stand-alone product effectively strips away any moderating influence, leaving users with a compound that behaves more like a new, unapproved opioid than a plant-based supplement. Public health authorities are keenly aware of this nuance. I
When it comes to 7-OH, the official tone is not ambivalent. The FDA’s consumer warnings stress that there are no approved uses for 7-OH in any medical or wellness context, and that products containing 7-OH as an added ingredient or at enhanced levels are unlawful as dietary supplements or food additives; regulators emphasize that consumers should avoid all such products and instead seek evidence-based treatments overseen by healthcare professionals, particularly when dealing with serious conditions like chronic pain, mood disorders, or substance use disorders. In effect, the agency is drawing a bright line between experimental, concentrated 7-OH products and the broader, still-evolving discussion around natural kratom.
All of this raises a critical question: does 7-OH serve any beneficial purpose outside the trace amounts that occur naturally in kratom leaves, or is it simply an unnecessary and dangerous distortion of a traditional plant? Based on the current regulatory record, there is no evidence that isolated or synthetic 7-OH provides unique therapeutic advantages that cannot be achieved through existing, regulated medications, but there is accumulating evidence that these products can contribute to addiction, overdose, and other serious harms; health agencies from the FDA to state departments of health and poison centers have not identified any legitimate role for 7-OH in consumer products and instead recommend avoidance.
By contrast, while natural kratom remains unapproved and controversial, it occupies a more complex space where potential benefits and risks coexist, and where careful, evidence-based regulation could play a role in reducing harm. Advocates argue that distinguishing clearly between natural kratom and 7-OH products—through accurate labeling, restrictions on synthetic and enhanced 7-OH ingredients, and transparent communication about dose and composition—would allow public health agencies to target the most dangerous products without dismissing the lived experiences of people who report benefit from traditional or minimally processed kratom.
For consumers, the practical takeaway is straightforward but vital. If a product is labeled as containing 7-hydroxymitragynine, 7-OH, or “enhanced kratom,” or if it promises extreme potency, rapid euphoria, or strong opioid-like effects, it should be treated with the utmost caution, if not avoided altogether; America’s Poison Centers advise the public to avoid products containing 7-OH and to consult healthcare professionals before using any supplement marketed for pain, energy, or mood, while the FDA explicitly recommends steering clear of 7-OH products. Meanwhile, individuals who choose to use natural kratom should understand that “natural” does not mean perfectly safe, that dose and frequency matter, and that open communication with healthcare providers is essential.
As lawmakers and regulators continue to wrestle with how best to address kratom and its derivatives, one principle seems clear: conflating natural kratom with highly concentrated or synthetic 7-OH obscures important differences that can mean the difference between a manageable risk and a devastating outcome. By acknowledging the nuanced reality—recognizing that natural kratom, used in traditional forms and doses, has a very different profile from modern 7-OH products—policy-makers can craft more precise interventions, and consumers can make more informed decisions, grounded not in marketing slogans but in the rapidly evolving scientific and regulatory record.